Yesterday I contacted my local Morgans office in relation to Neuren research.
Morgans do not officially cover Neuren but the advisor was quite up to date with Neuens drug progress via Head Office information. [Scott Power is Morgans chief Healthcare Analyst and is also associated with Horizon 3 Biotech]. The Morgans advisor indicated that Neurens $1B marketcap achievement was especially important as it opens the door to more significant investors who use market capitalisation as one of their criteria in their investment strategy.
Kens
Yesterday I contacted my local Morgans office in relation to...
-
- There are more pages in this discussion • 8,842 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |